Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib and Enasidenib in IDH2-mutated MPN/MF
NCT04281498Phase 2Completed
- Sponsor
- John Mascarenhas
- Start
- Jan 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of enasidenib in Myeloproliferative Neoplasm (MPN) and myelofibrosis (MF), sponsored by John Mascarenhas. Primary endpoint: Number of MPN Participants With Response at 6 months. Started Jan 2021; status: completed.
02
Drugs
enasidenib
03
Conditions
Myeloproliferative Neoplasm (MPN)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04281498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04281498.